Literature DB >> 11523055

Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value.

G Anastassiou1, S E Coupland, A Stang, R Boeloeni, H Schilling, N Bornfeld.   

Abstract

The interaction between Fas and Fas ligand is one possible immune escape mechanism used by tumour cells. In the present study, melanoma tissue from 103 patients who underwent enucleation for malignant uveal melanoma (iris melanomas excluded) was stained by immunohistochemistry with monoclonal antibodies specific for Fas, Fas ligand, CD3, CD8, and CD68. Histological and clinical data for these tumours were assessed. Both Fas and Fas ligand were detected in uveal melanomas. Cells of the monocyte/macrophage lineage rather than T-cells were the predominant group of tumour-infiltrating cells. The metastasis-free 5-year survival rates in the univariate analyses were considerably lower in patients with tumours that lacked Fas ligand expression (< 35% of the tumour cells), in the presence of more than 50 CD8-positive cells in 20 high-power fields and in the presence of more than 100 CD3-positive cells in 20 high-power fields. Fas and Fas ligand expression was associated with scleral infiltration. After adjustment for scleral infiltration, the predictive value of both Fas and Fas ligand expression was markedly decreased. In addition, the CD3- and CD8-positive cell count was positively associated with the histological cell type. Cox proportional hazards models showed that the presence of CD3- and CD8-positive cells was not an independent prognostic factor after adjusting for histological cell type. This preliminary observation deserves further investigation, which may shed more light on the immune escape mechanisms of this tumour and thus enable novel therapeutic strategies. The clinical relevance of this observation is limited, as more predictive parameters have been described for uveal melanoma. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523055     DOI: 10.1002/path.926

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

Review 2.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

3.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

Review 4.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

5.  Evidence of macrophage and lymphocyte, but not dendritic cell, infiltration in posterior uveal melanomas, whilst cultured uveal melanomas demonstrate pluripotency by expressing CD68 and CD163.

Authors:  Julia Woodward; Karen Sisley; Graham Reeves; Carmel Nichols; M Andrew Parsons; Hardeep Mudhar; Ian Rennie
Journal:  Int J Exp Pathol       Date:  2004-02       Impact factor: 1.925

6.  DNA alteration-based classification of uveal melanoma gives better prognostic stratification than immune infiltration, which has a neutral effect in high-risk group.

Authors:  Deepti Narasimhaiah; Catherine Legrand; Diane Damotte; Romain Remark; Marco Munda; Patrick De Potter; Pierre G Coulie; Miikka Vikkula; Catherine Godfraind
Journal:  Cancer Med       Date:  2019-04-25       Impact factor: 4.452

Review 7.  Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.

Authors:  Maria Sofia Basile; Emanuela Mazzon; Paolo Fagone; Antonio Longo; Andrea Russo; Matteo Fallico; Vincenza Bonfiglio; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.